急性ST段抬高型心肌梗死患者抗凝联合溶栓干预的护理配合

目的总结急性ST段抬高型心肌梗死(STEMI)患者抗凝联合溶栓干预的护理配合体会。方法选取76例STEMI患者,随机分为对照组和观察组,各38例。2组患者入院后,均接受抗凝联合溶栓治疗,对照组给予常规护理,观察组给予综合护理干预。比较2组患者急诊停留时间、急诊-溶栓再通时间及住院时间,观察治疗期间2组患者并发症发生情况。结果观察组急诊停留时间、急诊-溶栓再通时间及住院时间均显著短于对照组(P0.05);观察组治疗期间心力衰竭、心源性休克、皮下血肿发生率发生率显著低于对照组(P0.05)。结论加强对STEMI患者抗凝联合溶栓干预的护理配合,有利于提高急诊救治效率,降低并发症发生风险,缩短患者康复进程。     

血浆脑钠肽对急性心肌梗死溶栓患者心血管事件的评价

目的 探讨血浆脑钠肽(BNP)对急性心肌梗死(AMI)溶栓患者住院期间心血管事件发生的临床预测价值.方法 以2005-01-30～2008-08-19期间就诊于广州医学院第二附属医院急诊科、确诊急性ST段抬高心肌梗死(STEMI)并溶栓的62例患者为观察对象,收集其血浆BNP浓度,记录其在住院期间心血管事件的发生情况,并通过浓度危险分层统计处理.结果 STEMI溶栓后住院期间发生心力衰竭、梗死后心绞痛患者的BNP浓度明显高于未发生组(P<0.01),而两组BNP浓度在STEMI溶栓后出现死亡事件比较差异无统计学意义(P>0.05).BNP<100 pg/mL组病死率为0,BNP 100～500 pg/mL组为3.57%,BNP>500 pg/mL组为12.5%;不同BNP浓度组死亡、心力衰竭、梗死后心绞痛发生率比较差异有统计学意义(P<0.01).通过受试者操作特征(ROC)曲线测定BNP浓度对STEMI溶栓后心血管事件(包括死亡、心力衰竭、梗死后心绞痛)的预测,ROC曲线的曲线下面积(AUC)分别为0.811、0.945、0.945.结论 血浆BNP浓度对AMI急诊静脉溶栓后患者住院期间心血管事件(包括死亡、心力衰竭、梗死后心绞痛)的发生概率具有临床预测价值,能为临床医生对AMI溶栓后患者及早进行病情危险分层及预后估计提供临床依据.     

不同性别急性ST段抬高型心肌梗死患者临床特征及住院期间预后分析

目的总结不同性别急性ST段抬高型心肌梗死(ST-segment elevation myocardial infarction, STEMI)患者的临床特征、治疗方案及住院期间转归。方法回顾性分析1 686例(男1 224例,女462例)STEMI患者的临床资料。结果女性STEMI患者年龄[70.43(63.69,76.39)岁]较男性[61.21(50.90,70.22)岁]大,吸烟比率(3.03%)较男性(55.07%)低,前壁心肌梗死比率(60.17%)、合并心律失常比率(23.16%)、心率>100次/min比率(12.99%)及合并高血压、高胆固醇血症、糖尿病比率(56.71%、12.34%、22.08%)较男性(55.07%、17.08%、8.91%、43.06%、6.78%、13.81%)高(P<0.05)。女性患者保守治疗比率(57.36%)较男性(37.75%)高,溶栓治疗、择期行经皮冠状动脉介入术、发病12 h内再灌注治疗比率(20.35%、17.10%、27.27%)较男性(30.23%、24.92%、43.14%)低(P<0.05),入院至球囊扩张时间、入院至溶栓药物注射时间、发病至首次医疗接触时间等与男性比较差异无统计学意义(P>0.05)。女性患者住院期间病死率(6.28%)及不良心脑血管事件发生率(13.85%)均高于男性(2.37%、8.25%)(P<0.05)。广义线性混合模型调整年龄与中心效应后,女性为STEMI患者住院期间死亡(OR=2.32,95%CI:1.30~4.14,P=0.004)、发生不良心脑血管事件的独立危险因素(OR=1.76,95%CI:1.25~2.47,P=0.024)。结论与男性患者比较,女性STEMI患者住院病死率及不良心脑血管事件发生率较高,可能与年龄较大、合并较多的心血管疾病高危因素、多采取保守治疗有关。     

ST段抬高STEMI介入治疗后早期ST段下降幅度的临床意义及影响因素

[目的]探讨ST段抬高的急性心肌梗死(STEMI)患者急诊经皮冠状动脉介入治疗(PCI)成功后早期ST段下降幅度的临床意义及其影响因素.[方法]选择首次经急诊PCI术且TIMl血流达3级的98例STEMI患者,测量并比较PCI术前、术后1h梗死相关导联ST段下降幅度,以∑ST段下降≥50%为A组,＜50%为B组,分析住院期间的临床事件和可能影响ST段下降的相关因素.[结果]A组住院期间心脏主要不良事件的发生率明显低于B组(10.6%比40.6%,P＜0.01).两组比较,A组梗死前反复发作心绞痛者较多,B组合并糖尿病较多、发病至梗死相关动脉(IRA)再通时间较长,多因素Logistic逐步回归分析显示:糖尿病、发病至IRA再通时间是影响ST段下降幅度的独立危险因素(OR＞1,P＜0.05),梗死前反复发作心绞痛是ST段下降的有利因素(OR＜1,P＜0.05).[结论]STEMI患者急诊PCI术后早期ST段下降幅度能作为住院期间心脏主要不良事件发生情况的预测指标,糖尿病、梗死前心绞痛、发病至IRA再通时间是影响STEMI介入治疗后心电图ST段下降幅度的主要因素.     

急性脑梗死重组组织型纤溶酶原激活剂溶栓治疗出血转化的危险因素分析

目的:探讨急性脑梗死患者静脉应用重组组织型纤溶酶原激活剂(rt-PA)静脉溶栓后出血转化(HT)的危险因素。方法:回顾性分析2017-01—2018-12期间收治的245例接受rt-PA静脉溶栓治疗的急性脑梗死患者的临床资料,根据溶栓后是否发生出血转化分为HT组与非HT组(NHT组)。收集两组患者一般资料、发病至治疗时间(OTT)、溶栓前美国国立卫生院脑卒中量表(NIHSS)评分、实验室检查指标、影像学特点等资料。应用Logistic回归分析溶栓后出血转化的危险因素。结果:245例接受rt-PA溶栓的急性脑梗死患者发生HT的38例,占15.51%。单因素分析显示,年龄、吸烟史、溶栓前收缩压、溶栓前血糖、糖尿病史、心房颤动史、溶栓前NIHSS评分、OTT、血尿酸、脑白质疏松是急性脑梗死溶栓后HT的影响因素(P0.05);多因素Logistic回归分析结果显示,糖尿病(OR=0.737,95%CI:0.765～1.048)、溶栓前NIHSS评分(OR=0.590,95%CI:0.428～0.814)、OTT(OR=0.351,95%CI:0.530～1.185)、血尿酸(OR=0.954,95%CI:0.928～0.980)、溶栓前收缩压(OR=0.819,95%CI:0.737～0.910)、脑白质疏松(OR=0.459,95%CI:0.865～0.912)是急性脑梗死溶栓后HT的独立危险因素。结论:糖尿病、溶栓前NIHSS评分、OTT、血尿酸、溶栓前收缩压、脑白质疏松是急性脑梗死溶栓后HT的独立危险因素。因此,临床上针对此类患者进行rt-PA静脉溶栓治疗时应谨慎,避免不良事件的发生。     

急性脑梗死患者再通治疗预后的相关影响因素分析

目的：探讨影响急性脑梗死（ACI）患者再通治疗预后的相关影响因素。方法：回顾性分析2018年2月至2020年5月接诊的94例ACI患者的临床资料。患者均行静脉溶栓治疗,按预后情况分为预后良好41例,预后不良53例。收集两组一般及临床资料,分析影响ACI患者再通治疗预后的相关因素。结果：糖尿病、年龄、高血压、溶栓前美国国立卫生院卒中量表（NIHSS）评分、发病至溶栓时间、侧支循环不良与ACI患者再通治疗预后有关（P＜0.05）;性别、冠心病、高脂血症、吸烟史、梗死部位、饮酒史与ACI患者再通治疗预后无关（P＞0.05）;Logistic回归分析显示：年龄≥60岁（OR=3.407,95%置信区间=1.224~9.489）、糖尿病（OR=2.726,95%置信区间=1.089~6.824）、高血压（OR=3.102,95%置信区间=1.328~7.242）、发病至溶栓时间≥3.5 h（OR=3.746,95%置信区间=1.531~9.165）、溶栓前NIHSS评分≥8分（OR=8.220,95%置信区间=2.952~22.886）、侧支循环不良（OR=3.152,95%置信区间= 1.328~7.484）是影响ACI患者再通治疗预后的高危因素（P＜0.05且OR≥1）。结论：影响ACI患者再通治疗预后因素多样,针对各危险因素,临床需制定相应的防治措施,以改善预后。     

ST段抬高型急性心肌梗死rt-PA溶栓中再灌注心律失常的临床观察

目的观察ST段抬高型急性心肌梗死(STEMI)患者重组组织型纤溶酶原激活剂(rt-PA)静脉溶栓后再灌注心律失常的类型及其与冠脉再通的关系。方法57例STEMI患者经rt-PA静脉溶栓治疗,观察再灌注心律失常的发生情况,溶栓后90min进行冠脉造影,观察罪犯血管的再通情况。结果溶栓治疗中46例(80.7%)发生心律失常,冠脉造影再通(TIMIⅡ级或Ⅲ级)42例(73.7%),加速性室性自主心律多发生在再通组。结论STEMI溶栓治疗时再通组的再灌注心律失常以加速性室性自主心律最常见,它是提示冠脉再通的较可靠指标。     

急诊经皮冠状动脉介入后无复流的临床及程序危险因素分析

目的 探讨急性心肌梗死(acute myocardial infarction,AMI)患者急诊经皮冠状动脉介入(percutaneous coronaryintervention,PCI)术后出现无复流现象相关的危险因素.方法 连续选取2008年1月至2010年12月于上海市东方医院心内科住院的AMI患者312例为研究对象.入选标准:发病12 h内,或12 h至24 h内仍有持续缺血性胸痛,成功接受PCI手术治疗且资料完整者.排除标准:冠脉痉挛或罪犯病变直径狭窄程度≤50％、冠脉血流正常行保守治疗,严重左主干或三支血管病变需急诊冠脉搭桥术.根据PCI术后心肌梗死溶栓试验(TIMI)血流分级,患者分为正常血流组和无复流组.比较这两组患者基本临床资料、造影结果及手术相关资料的差异,采用单变量和多变量Logistic回归分析急性心肌梗死患者急诊PCI术后出现无复流现象的影响因素.结果 20.3％的患者急诊PCI术后出现了无复流.单变量分析:年龄、再灌注时间(症状至PCI的时间)、入院时收缩压、心梗Killip分级、急诊PCI术前应用主动脉内气囊反搏(intra-aortic balloon pump,IABP)、PCI术前TIMI血流分级、闭塞病变类型、血栓负荷、靶病变长度、参考血管直径、再灌注方法与无复流现象相关(P＜0.05).多变量Logistic回归模型分析发现,年龄＞65岁(OR=1.470,95％ CI 1.460～1.490,P=0.007)、再灌注时间＞6h(OR=1.270,95％ CI 1.160～1.400,P=0.001)、入院时低收缩压(＜100 mmHg)(1 mmHg=0.133 kPa) (OR=1.910,95％CI 1.018～3.896,P=0.004)、PCI术前应用IABP(OR=1.949,95％ CI 1.168 ～3.253,P=0.011)、PCI术前低(≤1)TIMI血流(OR=1.100,95％ CI 1.080 ～1.250,P＜0.01)、高血栓负荷(OR=1.600,95％ CI 1.470～2.760,P=0.030)、长靶病变(OR=1.948,95％ CI 1.908～1.990,P=0.019)是急诊PCI术后发生无复流现象的独立危险因素.结论 可根据急性心肌梗死患者临床、造影及手术时的发现来预测急诊PCI术后是否发生无复流现象.     

急诊应用不同溶栓药物治疗ST段抬高型心肌梗死回顾性分析

目的比较使用瑞替普酶(rPA)、阿替普酶(rt-PA)和重组链激酶(r-SK)对ST段抬高型心肌梗死(STEMI)患者进行静脉溶栓治疗的临床疗效。方法自2003-02~2006-12我院急诊科72例STEMI患者接受静脉溶栓治疗,其中rPA组24例,rt-PA组31例,r-SK组17例,统计治疗后血管再通率、死亡率及观察有无出血、心力衰竭、心源性休克等并发症。结果血管再通率:rPA组87.50%、rt-PA组83.87%及r-SK组70.59%,其中60min及90min再通率rPA组、rt-PA组高于r-SK组。溶栓后30d内再闭塞率、心力衰竭等并发症发生率三组比较差异无统计学意义(P>0.05)。死亡率:rPA组8.33%、rt-PA组6.45%及r-SK组11.76%。出血发生率:rPA组、rt-PA组高于r-SK组。结论rPA、rt-PA及r-SK均适合急诊科内STEMI患者的静脉溶栓治疗,rPA、rt-PA早期再通率高于r-SK。     

爱通立治疗急性ST段抬高型心肌梗死的疗效分析

目的探讨半剂量和全剂量重组人组织型纤溶酶原激活物(rtPA)溶栓药物爱通立治疗急性ST段抬高型心肌梗死(STEMI)的疗效。方法将216例STEMI患者根据给药方法不同分为半剂量组(n=118)和全剂量组(n=98),观察两组患者的冠状动脉血管再通率、出血不良反应、明显心律失常发生率。结果治疗后,半剂量组和全剂量组血管再通率分别78.4%(92/118)、83.3%(81/98),差异有统计学意义(P0.05)。两组出血不良反应及明显心律失常发生率差异无统计学意义(P0.05)。STEMI发病后3h内、3~6h、6~12h给予rtPA溶栓治疗的患者血管再通率分别为91.2%、73.9%、53.80%。结论 rtPA治疗STEMI的疗效肯定,安全可靠,尤其适用于无条件进行介入治疗的基层医院。     

尼可地尔对接受溶栓治疗再通的急性ST段抬高型心肌梗死患者的心肌保护效应

目的：评价静脉溶栓联合尼可地尔的治疗方案是否能够提高急性 ST 段抬高型心肌梗死（STEMI）患者的治疗效果。方法入选就诊于保定市第一中心医院行溶栓治疗的急性 STEMI 患者,随机分为尼可地尔组和对照组,尼可地尔组在确诊后即刻口服尼可地尔20 mg,之后5 mg 每日3次口服,对照组常规进行溶栓治疗,观察两组住院期间的心肌损伤程度,ST 段回落,急性期心律失常的发生率,心功能状况,以及随访6个月的心功能状况及随访期内不良心血管事件的发生率。结果共入选121例患者,尼可地尔组64例,对照组57例,两组基线资料无明显差异。溶栓后4、12、24小时监测的肌钙蛋白 I（cTNI）水平显示,两组在组间、不同时点以及组间和不同时点的交互作用差异均有统计学意义（P ＜0．05或＜0．01）,尼可地尔组 cTNI 水平明显低于对照组;溶栓后监测的患者心电图 ST 段回落情况显示,两组在组间、不同时点以及组间和不同时点的交互作用差异均有统计学意义（P ＜0．05或＜0．01）,尼可地尔组 ST 段回落明显大于对照组;急性期 Curtis-Walker 评分≥3分的比例尼可地尔组明显低于对照组（P ＜0．05）;室壁运动积分指数尼可地尔组明显低于对照组（P ＜0．05）;两组患者的不良心血管事件差异无统计学意义（P ＞0．05）。结论静脉溶栓联合口服尼可地尔治疗可进一步提高急性 STEMI 患者的心肌灌注水平,减少心肌损伤,改善心脏功能,减少心律失常的发生。     

ST段抬高型心肌梗死溶栓前后心肌缺血修饰白蛋白浓度与心肌再灌注的关系

[目的]观察ST段抬高型心肌梗死（STEMI）患者溶栓前后血管再通和心肌缺血修饰白蛋白（IMA）浓度变化,探讨两者之间的关系及临床意义.[方法]入选STEMI并于发病6 h之内入院患者共80例,均予常规及尿激酶溶栓治疗,根据2 h后有无再灌注表现将患者分成无灌注组（30例）和再灌注组（50例）,两组病人于溶栓前及溶栓后2 h、4 h、6 h分别采血测IMA浓度,并于8、12、14 h采血测肌酸激酶同工酶（CK-MB）浓度.[结果]两组患者溶栓前IMA浓度无明显差异,溶栓后4～6 hIMA浓度有显著差异（P〈0.05）;再灌注组于心肌再灌注恢复后,IMA提前达峰值并回落至正常,IMA达峰值时间较肌酸激酸同工酶（CK-MB）显著提前（P〈0.05）.[结论]STEMI溶栓后心肌是否恢复再灌注与IMA浓度变化存在相关性.IMA早期明显下降可作为STEMI溶栓后心肌恢复有效再灌注的指标.     

Detecting failed thrombolysis in the accident and emergency department

The primary objective in managing a patient with ST segment elevation myocardial infarction (STEMI) is to establish reperfusion in the infarct-related artery and to maintain it. Two approaches to coronary reperfusion are used in the UK - primary angioplasty and intravenous thrombolysis. Primary angioplasty is the gold standard approach to managing STEMI, but in the UK (due to financial, resource and personnel limitations) this is not the first-line treatment. Thrombolytic therapy remains the most widely used approach and the benefits of such an approach are irrefutable; thrombolysis saves lives, reduces infarct size and limits left ventricular dysfunction. However, data from the thrombolytic trials also suggest that 30-40% of patients fail to reperfuse with standard thrombolytic therapy. Similar data demonstrates that patients who do not sustain adequate perfusion in the infarct-related artery have a poor prognosis and increased mortality rates. As long as thrombolysis remains the standard therapy for STEMI, it is important that patients in whom the treatment has been unsuccessful are swiftly recognised and appropriate interventions instituted. The criteria to assess successful reperfusion of the infarct-related artery need to be simple to apply, easy to interpret and non-invasive. This article will discuss the most useful criteria to make such a diagnosis and suggest approaches to enable recognition of 'failed thrombolysis' in the accident and emergency department. The current views on managing failed thrombolysis will conclude the article.     

Angioplasty within 24 h after thrombolysis in patients with acute ST-elevation myocardial infarction: current use, predictors and outcome

Background  Percutaneous coronary intervention (PCI) early after thrombolysis (early PCI) in patients with ST-elevation myocardial infarction (STEMI) is currently advised by clinical guidelines, but little is known about its use in clinical practice. Methods  We analysed the MITRA (Maximal Individual Therapy of Acute Myocardial Infarction) plus registry. Results  Out of a total of 34276 patients with STEMI, 10600 (30.9%) were treated with intravenous thrombolysis. Out of these patients, 487 (4.6%) patients received an angioplasty between 61 min and 24 hours after thrombolysis. They were compared to 10113 (95.4%) patients who received PCI either later than 24 hours after thrombolysis or not at all. A continuous increase in the frequency of early PCI between the years 1994 (2%)-2002 (16.7%) was observed. After adjusting for confounding variables independent predictors to use early PCI were the increasing year of inclusion, the facility of the hospital to perform PCI, younger age and male gender. Hospital mortality was 7.2% in patients receiving early PCI, compared to 11.2% in the other group (<0.01). Independent predictors for a higher hospital mortality were shock, age >65 years, female gender, an anterior STEMI and a prehospital delay of >3 hours. However, early PCI was not longer associated with a lower mortality (OR 0.95, 95% CI 0.64–1.14). Conclusion  Early PCI after thrombolysis is used infrequently in current clinical practice in Germany. Especially ‘low risk’ patients were treated with an early PCI, which may contribute to the missing effect on mortality compared to no or late PCI after thrombolysis.     

BNP与hs-CRP联合检测对ST段抬高心肌梗死患者静脉溶栓效果的观察

目的通过持续12-导联ECGST段监测,评估血液中B型尿钠肽（BNP）、高敏C反应蛋白（hs—CRP）的检测对心肌梗死患者静脉溶栓效果预测的重要性。方法2003年8月到2007年12月间指标性疼痛发生6h内接受静脉内溶栓治疗的ST段拾高心肌梗死（sTEMI）连续患者共372例,溶栓失败是以静脉溶栓开始后90min内ST段恢复≤50％来认定。结果心肌梗死患者静脉溶栓失败率为57．4％,多变量Logistic回归分析BNP组（RR1．5;95％CI1．1～1．8,P=0．004高／中组;RR2．2,95％CI1．9～3．5,P=0．001高／低组;RR1．5,95％CI1．2～1．8,P=0．001中／低组）和hs—CRP组（RR2．0,95％CI1．6～2．2;P=0．001高／中组;RR2．6,95％CI 2．1～3．5,P=0．001高／低组;RR1.3,95％CI1．2～1．7,P=0．02中／低组）。均与溶栓失败的发生率显著相关。结论研究结果表明循环中BNP和hs—CRP的升高与溶栓失败的发生率显著相关。     

Type 2 diabetes and intravenous thrombolysis outcome in the setting of ST elevation myocardial infarction

OBJECTIVE: There are conflicting results regarding the impact of type 2 diabetes on intravenous thrombolysis effectiveness during ST elevation myocardial infarction (STEMI). The present study, using a continuous 12-lead electrocardiogram, examined the possible association of type 2 diabetes with both acute intravenous thrombolysis effectiveness and long-term prognosis in this setting. RESEARCH DESIGN AND METHODS: The study included 726 consecutive subjects (214 type 2 diabetic subjects) with STEMI who received intravenous thrombolysis in the first 6 h from index pain and were followed up for 3.5 years. RESULTS: Type 2 diabetic subjects had significantly lower incidence of sustained > or = 50% ST recovery than nondiabetic subjects (P = 0.03). Additionally, the former required a significantly greater time interval through the achievement of this criterion than the latter (P < 0.001). In both type 2 diabetic (P < 0.001) and nondiabetic subjects (P < 0.001), those who had not attained > or = 50% ST recovery were at significantly higher risk of cardiac death than subjects who had reached this criterion. The subjects who attained the above electrocardiographic criterion in > or = 60 min after thrombolysis initiation were at significantly higher risk compared with those who achieved this criterion in <60 min (P = 0.02). However, this association was true only for type 2 diabetic subjects (P = 0.01) and not for nondiabetic subjects (P = 0.9). CONCLUSIONS: The present study suggests that type 2 diabetes is a strong predictor of acute intravenous thrombolysis failure during STEMI. This finding may significantly contribute to the worse prognosis for type 2 diabetic subjects compared with nondiabetic ones in this setting.     

Primary percutaneous coronary intervention and thrombolysis improve survival in patients with ST-elevation myocardial infarction and pre-hospital resuscitation

Background

Patients with ST-elevation myocardial infarction (STEMI) surviving pre-hospital resuscitation represent a selected subgroup of patients with a very high adverse event rate. Only few data on the outcome of primary percutaneous coronary intervention (primary PCI) and thrombolysis in such patients are available.

Methods

We analysed the Maximal Individual Therapy of Acute Myocardial Infarction (MITRA) Plus registry. 1529 survivors of pre-hospital resuscitation with STEMI were included. 593 (38.8%) of those patients did not receive early reperfusion therapy, 793 (51.9%) patients received thrombolysis and 143 (9.4%) patients received primary PCI. Hospital mortality in patients receiving primary PCI or thrombolysis was adjusted for confounding factors with a propensity score analysis.

Results

Primary PCI as well as thrombolysis in survivors of pre-hospital resuscitation with STEMI were associated with a significant reduction of hospital mortality (OR: 0.29, 95% CI 0.17-0.50; and 0.74, 95% CI 0.54-0.99, respectively), while primary PCI was superior compared to thrombolysis (OR 0.50, 95% CI 0.30-0.84).

Conclusion

Reperfusion therapy improves mortality of patients with STEMI surviving pre-hospital resuscitation, while primary PCI seems to be more effective than thrombolysis.     

急性ST段抬高型心肌梗死尿激酶原选择性冠状动脉内溶栓联合介入治疗与直接冠状动脉内介入治疗的对比研究

目的 探讨急性ST段抬高型心肌梗死（STEMI）选择性冠状动脉内溶栓联合介入治疗与直接冠状动脉内介入治疗的疗效。方法 2018年10月 2019年10月就诊于巩义市人民医院STEMI患者61例,采用随机单盲方法分为对照组（直接PCI）、治疗组（溶栓+PCI）,纳入对照组31例,治疗组30例。观察两组冠状动脉血管TIMI血流分级、N末端B型利钠肽原（NT ProBNP）水平、左心室射血分数（LVEF）值和住院期间病死率、再梗死率、出血事件发生率。结果 治疗后,治疗组TIMI血流分级提高优于对照组（P＜0.05）。结论 冠状动脉内溶栓后介入治疗对比直接冠状动脉内介入治疗,更能改善患者心肌灌注水平,减少无复流的发生率,且同样能改善心功能和未增加住院期间出血事件的发生率。     

NT-ProBNP和Q波在ST段升高型急性心肌梗死溶栓治疗后的疗效监测价值

目的分析血浆N-端脑钠肽（NT—ProBNP）水平、Q波与ST段回落（STR）之间的相关性，评价血浆NT—ProBNP水平、Q波和STR在ST段升高型急性心肌梗死溶栓治疗后的疗效监测价值。方法收集82例STEMI病例，根据溶栓治疗后STR百分比分为STR（-）组（〈50％STR）和STR（＋）组（50％STR），测定血浆NT—ProBNP水平、血压、Q波、心率、LVEF、C反应蛋白（CRP）、血糖（GLU）、肌酐（Crea），计算肾小球滤过率（GRF）。结果2组间血浆NT-ProBNP、Q波、LVEF水平差异有统计学意义（P〈0．01）；Pearson’s相关性分析发现，血浆NT—ProBNP水平与STR之间呈显著负相关，相关系数为-0．205，P〈0．001；Logistic多元回归分析发现，Q波和血浆NT—ProBNP水平进入回归方程。结论NT—ProBNP水平与STR密切相关。Q波和血浆NT—ProBNP水平是STR回落不良的独立危险因素。联合NT—ProBNP、Q波和STR能更全面准确评价和监测STEMI溶栓治疗效果。     

心肌梗死行冠状动脉介入治疗后无复流现象临床分析

目的探讨急性ST段抬高型心肌梗死患者行急诊冠状动脉介入术治疗后无复流现象的影响因素及对预后的影响。方法行急诊冠状动脉介入治疗的急性ST段抬高型心肌梗死患者385例,根据治疗后TIMI血流情况分为无复流组（TIMIO～2级）及TIMI3级组,记录2组住院期间不良事件发生情况,分析无复流现象的影响因素及对预后的影响。结果本组患者行急诊冠状动脉介入术后无复流发生率为40％;应激性高血糖、高尿酸血症、高敏C反应蛋白〉3mg／L是急诊冠状动脉介入术后无复流现象发生的独立危险因素;无复流现象可增加患者住院期间病死率及复合终点事件发生率。结论急诊冠状动脉介入术治疗急性ST段抬高型心肌梗死患者后无复流现象发生率高,无复流现象可增加心血管不良事件发生率。